Stay updated on Pembrolizumab in Pediatric Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Pediatric Solid Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Pediatric Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedAn additional recruitment site in Chicago, Illinois (Investigational Site 0024) has been added. This update increases the total number of locations from 16 to 17.SummaryDifference0.4%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe study's listed locations were updated from 17 to 16, with the Cincinnati, Ohio site removed from the recruitment roster. The overall location count now reflects 16 participating sites.SummaryDifference0.4%

- Check23 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous Revision: v3.5.3, indicating a small internal update. This update does not appear to alter the study information or other user-facing content.SummaryDifference0.0%

- Check30 days agoChange DetectedAmendment 13 closed enrollment for rrCHL, MSI-H solid tumors, TMB-H solid tumors, and 12 to <18 years old with advanced melanoma, and Amendment 8 closed enrollment for solid tumors and melanoma in 6 months to <12 years old. These changes narrow participant eligibility and reflect updates to the study plan.SummaryDifference0.9%

- Check45 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in Pediatric Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Pediatric Solid Tumors Clinical Trial page.